ROR1 and B-cell chronic lymphocytic leukemia: A total of 108 CLL patients received BTKi therapy (i.e., acalabrutinib, ibrutinib, spebrutinib, or zanubrutinib) as monotherapy (n = 40) or combined with venetoclax (n = 40), or an antibody (i.e., anti-CD20 rituximab), anti-ROR1 cirmtuzumab, or anti-PDL1 nivolumab (n = 10), or combined with chemotherapy (fludarabine, cyclophosphamide, or obinutuzumab (iFCG therapy), n = 18).